Takara Bio Inc
TSE:4974
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
941
1 276
|
| Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Takara Bio Inc
Takara Bio Inc
Cash & Cash Equivalents
Takara Bio Inc
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Takara Bio Inc
TSE:4974
|
Cash & Cash Equivalents
¥38B
|
CAGR 3-Years
6%
|
CAGR 5-Years
14%
|
CAGR 10-Years
5%
|
|
|
GNI Group Ltd
TSE:2160
|
Cash & Cash Equivalents
¥16.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
21%
|
CAGR 10-Years
13%
|
|
|
PeptiDream Inc
TSE:4587
|
Cash & Cash Equivalents
¥50.4B
|
CAGR 3-Years
60%
|
CAGR 5-Years
43%
|
CAGR 10-Years
31%
|
|
|
Pharma Foods International Co Ltd
TSE:2929
|
Cash & Cash Equivalents
¥15.7B
|
CAGR 3-Years
17%
|
CAGR 5-Years
29%
|
CAGR 10-Years
26%
|
|
|
S
|
StemRIM Inc
TSE:4599
|
Cash & Cash Equivalents
¥8.4B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
27%
|
CAGR 10-Years
N/A
|
|
|
C
|
Cuorips Inc
TSE:4894
|
Cash & Cash Equivalents
¥5.6B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Takara Bio Inc
Glance View
Takara Bio, Inc. engages in development and marketing of genetic engineering technologies. The company is headquartered in Kusatsu-Shi, Shiga-Ken and currently employs 1,539 full-time employees. The company went IPO on 2004-12-07. The firm operates in three business segments. Bioindustry Support segment provides reagents for research (genetic engineering reagents, cell engineering reagents, protein engineering reagents), scientific instruments, contract services and license fees for gene related patents to research institutes, such as universities and companies where biotechnology research and development are conducted. Gene Medicine segment provides gene therapy-related development and sale licensing fees and trial products as an application field of genetic engineering technology and cell engineering technology which is core technology cultivated in development of research reagents. Medical Food and Biotechnology segment provides health food and health food research and development services, license fees for health food related patents, as well as license fees for mushrooms.
See Also
What is Takara Bio Inc's Cash & Cash Equivalents?
Cash & Cash Equivalents
38B
JPY
Based on the financial report for Jun 30, 2024, Takara Bio Inc's Cash & Cash Equivalents amounts to 38B JPY.
What is Takara Bio Inc's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
5%
Over the last year, the Cash & Cash Equivalents growth was -17%. The average annual Cash & Cash Equivalents growth rates for Takara Bio Inc have been 6% over the past three years , 14% over the past five years , and 5% over the past ten years .
You don't have any saved screeners yet
